{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Source:
NCT02306811: Phase 2 Interventional Terminated Relapsing-remitting Multiple Sclerosis
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:foravirumab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04584697: Phase 1/Phase 2 Interventional Withdrawn Covid19
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04596150: Phase 2 Interventional Completed Neoplasms
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:efzimfotase alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT00679289: Phase 2 Interventional Completed Metastatic Melanoma
(2008)
Source URL:
Class:
PROTEIN
Class:
PROTEIN
Pegorgotein (formerly known as PEG-SOD) was developed by Enzon pharmaceutical as a scavenger of oxygen-derived free radicals. This drug under the trade name DISMUTEC participated in phase III clinical trial in patients with a severe closed head injury. It was found that the drug failed to show a statistically significant difference between the treatment group and the control group. In spite of DISMUTEC exhibited longer circulating half-life and reduced immunogenicity; however, the drug showed insufficient therapeutic effect for this indication. In addition, pegorgotein was studied for patients with reperfusion injury and stroke. However, these studies were also discontinued.
Status:
Investigational
Source:
NCT03047928: Phase 1/Phase 2 Interventional Completed Metastatic Melanoma
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT02482441: Phase 1 Interventional Completed Advanced Relapsed Tumors
(2015)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:camidanlumab [INN]
Source URL:
Class:
PROTEIN
